Comparative Pharmacology
Head-to-head clinical analysis: ARANELLE versus OVULEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARANELLE versus OVULEN.
ARANELLE vs OVULEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Ovulen is a combination oral contraceptive containing ethynodiol diacetate (a progestin) and mestranol (an estrogen). It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. It also increases cervical mucus viscosity and alters endometrial development, impeding sperm penetration and implantation.
One tablet (norethindrone 1 mg and ethinyl estradiol 20 mcg) orally once daily for 21 days, followed by 7 days of placebo.
1 tablet (1 mg ethynodiol diacetate, 50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo or no medication.
None Documented
None Documented
Terminal half-life 12-14 hours; steady-state achieved within 2-3 days; clinical context supports once-daily dosing
Ethinylestradiol: 10-20 hours (mean 17 hours); Dimethisterone: 10-15 hours. Clinical context: Steady state achieved after 3-5 days; elimination prolonged in hepatic impairment.
Renal 50-60% as metabolites (sulfate and glucuronide conjugates), fecal 30-40%, biliary 10%
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates), biliary/fecal: 40-50% (enterohepatic circulation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive